The prevalence of obesity continues to remain high in the US making the demand for effective treatments even more urgent.

For years, people looking for weight management support have turned to injectable medications like Ozempic, which contains ...

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 ...

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all ...

In Washington state, four agricultural workers tested presumptively positive for avian influenza after contact with infected ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

Schally, PhD-- who won a Nobel Prize for discovering the hormones used by the brain to control growth, reproduction, and ...